<DOC>
	<DOCNO>NCT01908426</DOCNO>
	<brief_summary>The purpose study evaluate effect Cabozantinib ( XL184 ) compare placebo overall survival subject advance hepatocellular carcinoma receive prior sorafenib .</brief_summary>
	<brief_title>Study Cabozantinib ( XL184 ) v Placebo Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Select 1 . Histological cytological diagnosis HCC . 2 . The subject disease amenable curative treatment approach . 3 . Received prior sorafenib . 4 . Progression follow least 1 prior systemic treatment HCC . 5 . Recovery toxicity relate prior treatment . 6 . ECOG performance status 0 1 . 7 . Adequate hematologic renal function , base upon meet protocol define laboratory criterion within 7 day randomization . 8 . ChildPugh Score A . 9 . Antiviral therapy per local standard care active hepatitis B ( HBV ) infection . 10 . Sexually active fertile subject ( male female ) must agree use medically accept method contraception course study 4 month last dose study treatment . 11 . Female subject childbearing potential must pregnant screening . Select 1 . Fibrolamellar carcinoma mixed hepatocellular cholangiocarcinoma . 2 . Receipt 2 prior systemic therapy advance HCC . 3 . Any type anticancer agent ( include investigational ) within 2 week randomization . 4 . Radiation therapy within 4 week ( 2 week radiation bone metastasis ) radionuclide treatment within 6 week randomization . 5 . Prior cabozantinib treatment . 6 . Known brain metastasis cranial epidural disease unless adequately treat radiotherapy and/or surgery stable least 3 month randomization . 7 . Concomitant anticoagulation , therapeutic dos , anticoagulant . 8 . Serious illness cancer would preclude safe participation study . 9 . Subjects untreated incompletely treated varix bleed high risk bleeding . 10 . Moderate severe ascites . 11 . Pregnant lactating female . 12 . Diagnosis another malignancy within 2 year randomization , except superficial skin cancer , localize , lowgrade tumor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>cabozantinib</keyword>
	<keyword>XL184</keyword>
	<keyword>liver cancer</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
	<keyword>MET</keyword>
	<keyword>vascular endothelial growth factor receptor 2 ( VEGFR2 )</keyword>
</DOC>